ARGENX SE (ARGX.BR) Stock Fundamental Analysis
Europe - Euronext Brussels - EBR:ARGX - NL0010832176 - Common Stock
695.6 EUR
-1.4 (-0.2%)
Overall ARGX gets a fundamental rating of 6 out of 10. We evaluated ARGX against 83 industry peers in the Biotechnology industry. ARGX is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. ARGX is not priced too expensively while it is growing strongly. Keep and eye on this one! With these ratings, ARGX could be worth investigating further for growth investing!.
1. Profitability
1.1 Basic Checks
In the past year ARGX was profitable.
ARGX had a positive operating cash flow in the past year.
In the past 5 years ARGX reported 4 times negative net income.
In the past 5 years ARGX always reported negative operating cash flow.
1.2 Ratios
The Return On Assets of ARGX (17.84%) is better than 91.57% of its industry peers.
Looking at the Return On Equity, with a value of 21.00%, ARGX belongs to the top of the industry, outperforming 90.36% of the companies in the same industry.
With a decent Return On Invested Capital value of 5.71%, ARGX is doing good in the industry, outperforming 79.52% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 17.84% | ||
| ROE | 21% | ||
| ROIC | 5.71% |
ROA(3y)-5.23%
ROA(5y)-11.34%
ROE(3y)-5.76%
ROE(5y)-13.95%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
ARGX's Profit Margin of 41.97% is amongst the best of the industry. ARGX outperforms 91.57% of its industry peers.
The Operating Margin of ARGX (15.30%) is better than 81.93% of its industry peers.
ARGX has a Gross Margin of 89.40%. This is amongst the best in the industry. ARGX outperforms 80.72% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 15.3% | ||
| PM (TTM) | 41.97% | ||
| GM | 89.4% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so ARGX is destroying value.
ARGX has more shares outstanding than it did 1 year ago.
The number of shares outstanding for ARGX has been increased compared to 5 years ago.
ARGX has a worse debt/assets ratio than last year.
2.2 Solvency
ARGX has an Altman-Z score of 29.27. This indicates that ARGX is financially healthy and has little risk of bankruptcy at the moment.
ARGX has a better Altman-Z score (29.27) than 97.59% of its industry peers.
ARGX has a debt to FCF ratio of 0.14. This is a very positive value and a sign of high solvency as it would only need 0.14 years to pay back of all of its debts.
ARGX has a Debt to FCF ratio of 0.14. This is amongst the best in the industry. ARGX outperforms 93.98% of its industry peers.
A Debt/Equity ratio of 0.01 indicates that ARGX is not too dependend on debt financing.
ARGX's Debt to Equity ratio of 0.01 is amongst the best of the industry. ARGX outperforms 85.54% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | 0.14 | ||
| Altman-Z | 29.27 |
ROIC/WACC0.77
WACC7.43%
2.3 Liquidity
A Current Ratio of 5.60 indicates that ARGX has no problem at all paying its short term obligations.
The Current ratio of ARGX (5.60) is better than 85.54% of its industry peers.
ARGX has a Quick Ratio of 5.27. This indicates that ARGX is financially healthy and has no problem in meeting its short term obligations.
ARGX has a better Quick ratio (5.27) than 86.75% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.6 | ||
| Quick Ratio | 5.27 |
3. Growth
3.1 Past
ARGX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 1512.50%, which is quite impressive.
The Revenue has grown by 64.71% in the past year. This is a very strong growth!
Measured over the past years, ARGX shows a very strong growth in Revenue. The Revenue has been growing by 94.61% on average per year.
EPS 1Y (TTM)1512.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%272.66%
Revenue 1Y (TTM)64.71%
Revenue growth 3Y63.92%
Revenue growth 5Y94.61%
Sales Q2Q%95.51%
3.2 Future
Based on estimates for the next years, ARGX will show a very strong growth in Earnings Per Share. The EPS will grow by 107.34% on average per year.
ARGX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 34.98% yearly.
EPS Next Y935.48%
EPS Next 2Y313.05%
EPS Next 3Y178.04%
EPS Next 5Y107.34%
Revenue Next Year95.19%
Revenue Next 2Y63.47%
Revenue Next 3Y48.27%
Revenue Next 5Y34.98%
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 65.31, the valuation of ARGX can be described as expensive.
Based on the Price/Earnings ratio, ARGX is valued a bit cheaper than 75.90% of the companies in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 27.00, ARGX is valued quite expensively.
The Price/Forward Earnings ratio is 27.51, which means the current valuation is very expensive for ARGX.
Based on the Price/Forward Earnings ratio, ARGX is valued a bit cheaper than 79.52% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 23.70, ARGX is valued at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 65.31 | ||
| Fwd PE | 27.51 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, ARGX is valued a bit cheaper than 72.29% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, ARGX is valued a bit cheaper than 79.52% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 161.96 | ||
| EV/EBITDA | 90.78 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as ARGX's earnings are expected to grow with 178.04% in the coming years.
PEG (NY)0.07
PEG (5Y)N/A
EPS Next 2Y313.05%
EPS Next 3Y178.04%
5. Dividend
5.1 Amount
No dividends for ARGX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
EBR:ARGX (1/9/2026, 4:44:16 PM)
695.6
-1.4 (-0.2%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners43.42%
Inst Owner ChangeN/A
Ins Owners0.12%
Ins Owner ChangeN/A
Market Cap42.83B
Revenue(TTM)3.60B
Net Income(TTM)1.28B
Analysts83.2
Price Target837.1 (20.34%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)15.16%
Min EPS beat(2)7.11%
Max EPS beat(2)23.2%
EPS beat(4)3
Avg EPS beat(4)3962.36%
Min EPS beat(4)-38.07%
Max EPS beat(4)15857.2%
EPS beat(8)5
Avg EPS beat(8)1996.71%
EPS beat(12)8
Avg EPS beat(12)1343.38%
EPS beat(16)12
Avg EPS beat(16)1012.62%
Revenue beat(2)1
Avg Revenue beat(2)3.68%
Min Revenue beat(2)-0.81%
Max Revenue beat(2)8.17%
Revenue beat(4)3
Avg Revenue beat(4)5.02%
Min Revenue beat(4)-0.81%
Max Revenue beat(4)8.17%
Revenue beat(8)6
Avg Revenue beat(8)5.96%
Revenue beat(12)10
Avg Revenue beat(12)14%
Revenue beat(16)13
Avg Revenue beat(16)17.53%
PT rev (1m)1.2%
PT rev (3m)13.84%
EPS NQ rev (1m)-0.95%
EPS NQ rev (3m)0.11%
EPS NY rev (1m)-0.42%
EPS NY rev (3m)14.37%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.56%
Revenue NY rev (1m)0.12%
Revenue NY rev (3m)5.34%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 65.31 | ||
| Fwd PE | 27.51 | ||
| P/S | 16.39 | ||
| P/FCF | 161.96 | ||
| P/OCF | 123.84 | ||
| P/B | 8.2 | ||
| P/tB | 8.51 | ||
| EV/EBITDA | 90.78 |
EPS(TTM)10.65
EY1.53%
EPS(NY)25.28
Fwd EY3.63%
FCF(TTM)4.29
FCFY0.62%
OCF(TTM)5.62
OCFY0.81%
SpS42.44
BVpS84.8
TBVpS81.76
PEG (NY)0.07
PEG (5Y)N/A
Graham Number142.55
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 17.84% | ||
| ROE | 21% | ||
| ROCE | 7.61% | ||
| ROIC | 5.71% | ||
| ROICexc | 15.87% | ||
| ROICexgc | 17.62% | ||
| OM | 15.3% | ||
| PM (TTM) | 41.97% | ||
| GM | 89.4% | ||
| FCFM | 10.12% |
ROA(3y)-5.23%
ROA(5y)-11.34%
ROE(3y)-5.76%
ROE(5y)-13.95%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.43
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | 0.14 | ||
| Debt/EBITDA | 0.07 | ||
| Cap/Depr | 428.74% | ||
| Cap/Sales | 3.12% | ||
| Interest Coverage | 519.07 | ||
| Cash Conversion | 82.6% | ||
| Profit Quality | 24.11% | ||
| Current Ratio | 5.6 | ||
| Quick Ratio | 5.27 | ||
| Altman-Z | 29.27 |
F-Score6
WACC7.43%
ROIC/WACC0.77
Cap/Depr(3y)176.19%
Cap/Depr(5y)545.91%
Cap/Sales(3y)10.66%
Cap/Sales(5y)13.77%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)1512.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%272.66%
EPS Next Y935.48%
EPS Next 2Y313.05%
EPS Next 3Y178.04%
EPS Next 5Y107.34%
Revenue 1Y (TTM)64.71%
Revenue growth 3Y63.92%
Revenue growth 5Y94.61%
Sales Q2Q%95.51%
Revenue Next Year95.19%
Revenue Next 2Y63.47%
Revenue Next 3Y48.27%
Revenue Next 5Y34.98%
EBIT growth 1Y208.18%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year1529.77%
EBIT Next 3Y219.36%
EBIT Next 5Y122.64%
FCF growth 1Y140.74%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y161.76%
OCF growth 3YN/A
OCF growth 5YN/A
ARGENX SE / ARGX.BR FAQ
What is the fundamental rating for ARGX stock?
ChartMill assigns a fundamental rating of 6 / 10 to ARGX.BR.
What is the valuation status for ARGX stock?
ChartMill assigns a valuation rating of 6 / 10 to ARGENX SE (ARGX.BR). This can be considered as Fairly Valued.
Can you provide the profitability details for ARGENX SE?
ARGENX SE (ARGX.BR) has a profitability rating of 5 / 10.
What are the PE and PB ratios of ARGENX SE (ARGX.BR) stock?
The Price/Earnings (PE) ratio for ARGENX SE (ARGX.BR) is 65.31 and the Price/Book (PB) ratio is 8.2.
What is the earnings growth outlook for ARGENX SE?
The Earnings per Share (EPS) of ARGENX SE (ARGX.BR) is expected to grow by 935.48% in the next year.